MedPath

Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole

Phase 4
Completed
Conditions
Short Stature
Interventions
Registration Number
NCT02137538
Lead Sponsor
Stanford University
Brief Summary

The purpose of the study is to determine if there are differences in the final height or hormone profile of short pubertal boys placed on different forms of aromatase inhibitor now routinely used to increase stature: Anastrozole and Letrozole. It also should determine if there are differences in the side effect profiles of the two drugs to be used.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
79
Inclusion Criteria
  • Current height less than 5th percentile AND/OR
  • Predicted adult height (based on bone age) more than 10 cm below target height (mid parental height)
  • Evidence of puberty: physical signs and serum luteinizing hormone > 0.3 IU/L and testosterone > 15 ng/dl
Exclusion Criteria
  • Bone age reading more than 14.0 years
  • Follicle stimulating hormone > 20 IU/L

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
LetrozoleLetrozoleLetrozole 2.5 mg daily
AnastrozoleAnastrozoleAnastrozole 1 mg daily
Primary Outcome Measures
NameTimeMethod
Predicted Adult Height at Year 3Year 3

Heights will be obtained by physical exam every 6 months during treatment. Skeletal maturation will be assessed from an x-ray by the method of Greulich and Pyle at baseline and every 12 months until the end of treatment.

Predicted adult height will be calculated at baseline and at the end of treatment based upon measured height and skeletal maturation (bone age).

Secondary Outcome Measures
NameTimeMethod
Inhibin BBaseline, year 3
Follicle Stimulating HormoneBaseline, year 3
Serum TestosteroneBaseline, year 3
AndrostenedioneBaseline, year 3
DihydrotestosteroneBaseline, year 3
Luteinizing HormoneBaseline, year 3
EstradiolBaseline, year 3
Number of Adverse Events Related to Acne or Bone Fracture3 years
Insulin-like Growth Factor Type 1Baseline, year 3
EstroneBaseline, year 3

Trial Locations

Locations (1)

Lucile Packard Children's Hospital

🇺🇸

Palo Alto, California, United States

© Copyright 2025. All Rights Reserved by MedPath